Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/70017
DC FieldValueLanguage
dc.contributor.authorFornell-Perez, R.en_US
dc.contributor.authorPérez Alonso, Estebanen_US
dc.contributor.authorAlemán-Flores, Patriciaen_US
dc.contributor.authorLozano-Rodriguez, A.en_US
dc.contributor.authorLoro Ferrer, Juan Franciscoen_US
dc.date.accessioned2020-02-05T12:51:56Z-
dc.date.available2020-02-05T12:51:56Z-
dc.date.issued2020en_US
dc.identifier.issn0009-9260en_US
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/70017-
dc.description.abstractTo analyse changes in post-neoadjuvant follow-up magnetic resonance imaging (MRI) staging accuracy for malignant adenopathies in rectal cancer, by comparing size criteria with morphological criteria using high-resolution T2-weighted sequences, as well as variations when adding diffusion-weighted imaging. METHODS AND MATERIALS: The present study was a cross-sectional study of a database including 46 1.5-T MRI examinations (2011–2016) from patients with biopsy-proven rectal cancer and chemoradiotherapy treatment before surgery. All cases were reviewed by three radiologists individually, who were blinded to any clinical information. The radiologists were experienced in rectal cancer (3–6 years) and evaluated the presence of malignant nodes in each patient. Malignancy was determined using morphological, size (5 mm), and diffusion criteria separately, as well as morphology plus diffusion. Each case was assessed four times: (1) evaluation of morphological criteria; (2) size criteria; (3) evaluation only using diffusion (b-values 50, 400, and 800); and (4) diffusion plus morphological criteria. Histological staging of surgical specimens was the reference standard. Statistical analysis included accuracy (area under the receiver operating characteristic [ROC] curve [AUC]), sensitivity, specificity, and positive/negative predictive values (PPV/NPV) for each radiologist, and group agreement (Fleiss' kappa). RESULTS: Mean values using morphological criteria were: AUC 0.78, sensitivity 77.7%, specificity 73.8%, PPV 66.1%, NPV 85.2%. Using size criterion: AUC 0.75, sensitivity 62.9%, specificity 83.2%, PPV 74.1%, NPV 80%. Added diffusion yielded no improvement, and yielded worse results by itself. CONCLUSIONS: Although morphological criteria showed better results in accuracy, sensitivity, and NPV, size criterion yielded the best specificity and PPV. Adding diffusion did not demonstrate a clear advantage over the criteria by themselves. Thus, mixed size–morphology criteria could have the greatest diagnostic value for follow-up N-staging.en_US
dc.languageengen_US
dc.relation.ispartofClinical radiology (Harlow. Print)en_US
dc.sourceClinical Radiology [ISSN 0009-9260], v. 75 (2), p. 100-107en_US
dc.subject320111 Radiologíaen_US
dc.subject.otherTotal Mesorectal Excision-
dc.subject.otherLymph-Nodes-
dc.subject.otherChemoradiation-
dc.subject.otherAccuracy-
dc.subject.otherValidation-
dc.subject.otherManagement-
dc.subject.otherSurvival-
dc.titleNodal staging in the rectal cancer follow-up MRI after chemoradiotherapy: use of morphology, size, and diffusion criteriaen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.crad.2019.08.003en_US
dc.identifier.scopus85071871708-
dc.identifier.isi000504760200003-
dc.contributor.authorscopusid36187744400-
dc.contributor.authorscopusid57205404424-
dc.contributor.authorscopusid23471848200-
dc.contributor.authorscopusid37117409600-
dc.contributor.authorscopusid8256199100-
dc.description.lastpage107en_US
dc.identifier.issue2-
dc.description.firstpage100en_US
dc.relation.volume75en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid8866334-
dc.contributor.daisngid32011971-
dc.contributor.daisngid6193922-
dc.contributor.daisngid6665551-
dc.contributor.daisngid15760648-
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:Fornell-Perez, R-
dc.contributor.wosstandardWOS:Perez-Alonso, E-
dc.contributor.wosstandardWOS:Aleman-Flores, P-
dc.contributor.wosstandardWOS:Lozano-Rodriguez, A-
dc.contributor.wosstandardWOS:Loro-Ferrer, JF-
dc.date.coverdateFebrero 2020en_US
dc.identifier.ulpgces
dc.description.sjr0,778
dc.description.jcr2,35
dc.description.sjrqQ2
dc.description.jcrqQ3
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.deptGIR Bioquímica Farmacológica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.orcid0000-0002-0517-8209-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNamePérez Alonso, Esteban-
crisitem.author.fullNameLoro Ferrer, Juan Francisco-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

1
checked on Jun 26, 2022

WEB OF SCIENCETM
Citations

2
checked on Jun 26, 2022

Page view(s)

56
checked on Jan 29, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.